Skip to main content
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. logo

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 301520 ISIN · CNE1000068J8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301520

About Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

https://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co., Ltd. is a comprehensive pharmaceutical research and development service provider specializing in clinical research and technical services. Operating primarily as a Contract Research Organization (CRO), the company offers a wide range of services including bioequivalence (BE) studies, Phase I through IV clinical trials, and pharmacokinetics (PK/PD) research. It provides end-to-end solutions for pharmaceutical development, encompassing clinical trial design, site management, data management, and statistical analysis. The firm focuses on supporting generic drug consistency evaluations and the development of innovative drugs. By maintaining advanced laboratory facilities and clinical research centers, the company ensures compliance with international quality standards and regulatory requirements to facilitate the market entry of diverse therapeutic products.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 annual shareholders’ meeting resolutions for Anhui Wanbang Pharmaceutical Technology Co., Ltd., detailing meeting attendance and the voting results on multiple proposals (board report, annual report, financial statements, profit distribution, compensation plan, governance amendments, etc.). It reports the vote tallies and confirmation by legal counsel, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-15 Chinese
安徽承义律师事务所关于安徽万邦医药科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (法律意见书) provided by a law firm regarding the legality of the company’s 2025 annual shareholders’ meeting, including descriptions of the convening procedures, attendee qualifications, voting process, and results. It does not itself constitute the annual report, proxy solicitation materials, or financial statements, nor is it an earnings release or similar. It is an attestation/certification by external counsel, which per the Certification Rule falls under Regulatory Filings (RNS) as a fallback for officer certifications and legal opinion letters.
2026-05-15 Chinese
关于安徽万邦医药科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings
2026-05-07 Chinese
关于安徽万邦医药科技股份有限公司2025年度持续督导现场检查报告
Regulatory Filings
2026-05-07 Chinese
关于举办2025年度业绩说明会的公告
Regulatory Filings
2026-05-07 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽万邦医药科技股份有限公司2026年第一季度报告" which translates to "Anhui Wanbang Pharmaceutical Technology Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is not a brief announcement or a certification letter but a full interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.